Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $603.3 million, representing a year-over-year increase of 14.2% and 13.8% on a constant currency basis [9][10] - EBITDA for Q2 2025 was $130.5 million, an increase of 16.2% compared to $112.3 million in Q2 2024, with an EBITDA margin of 21.6% [11][12] - Net income for Q2 2025 was $90.3 million, a 2.2% increase from $88.4 million in the prior year [12] Business Line Data and Key Metrics Changes - Net new business awards entering backlog in Q2 increased by 12.6% year-over-year to $620.5 million, resulting in a net book-to-bill ratio of 1.03 [9] - Ending backlog as of June 30, 2025, was approximately $2.9 billion, a decrease of 1.8% from the prior year [9] Market Data and Key Metrics Changes - The funding environment has stabilized and improved, allowing most clients with ongoing studies to secure sufficient funding [8] - The company anticipates a shift in business towards faster-burning therapeutic areas, which have a higher concentration of reimbursable costs [14] Company Strategy and Development Direction - The company raised its revenue guidance for 2025 by $280 million at the midpoint, now expecting total revenue in the range of $2.42 billion to $2.52 billion [14] - The strategy includes focusing on faster-burning therapeutic areas and improving operational efficiency to enhance productivity [10][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about accelerating revenue in the second half of the year due to improved funding, fewer cancellations, and rapid project start-ups [8] - There is a cautious outlook regarding potential future cancellations, which could impact 2026 revenue growth [29][30] Other Important Information - The company repurchased approximately 1.75 million shares for $518.5 million in Q2 2025, with $826.3 million remaining under the share repurchase authorization program [13] - The effective tax rate for 2025 is expected to be between 18.5% and 19% [14] Q&A Session Summary Question: What are the booking expectations for the second half? - Management expects bookings to increase, with a reasonable chance of achieving a book-to-bill ratio above 1.15, depending on cancellation rates [18] Question: Can you provide information on cancellations? - Cancellations were down across the portfolio, with rates lower than historical averages, contributing to better-than-expected performance [19] Question: How does the increased guidance break down between pass-through and direct revenue? - The increase is largely due to accelerated reimbursable cost activity, but there is also improved productivity from existing staff [24] Question: What is the outlook for funding and demand? - Management is cautious about the weak funding environment but has visibility into awarded projects that should support bookings [28][29] Question: What characterized the win rate this quarter? - The win rate was lower due to the loss of a few large projects, but overall decisions increased, leading to good new awards [46][52] Question: What is the expected hiring trend for the second half? - The company anticipates accelerated hiring in the second half, aiming for mid to upper single-digit growth in headcount [82][101]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $603.3 million, representing a year-over-year increase of 14.2% and 13.8% on a constant currency basis [10][12] - EBITDA for Q2 2025 was $130.5 million, an increase of 16.2% compared to $112.3 million in Q2 2024, with an EBITDA margin of 21.6% [11][12] - Net income for Q2 2025 was $90.3 million, a 2.2% increase from $88.4 million in the prior year [12] Business Line Data and Key Metrics Changes - Net new business awards entering backlog in Q2 increased by 12.6% year-over-year to $620.5 million, resulting in a net book-to-bill ratio of 1.03 [8][10] - Ending backlog as of June 30, 2025, was approximately $2.9 billion, a decrease of 1.8% from the prior year [8] Market Data and Key Metrics Changes - The company anticipates that approximately $1.75 billion of backlog will convert to revenue in the next twelve months, with a backlog conversion rate of 21.2% in Q2 [9][10] - The funding environment has stabilized and improved, allowing most clients with ongoing studies to secure sufficient funding [7][10] Company Strategy and Development Direction - The company raised its revenue guidance for 2025 by $280 million at the midpoint, now expecting total revenue in the range of $2.42 billion to $2.52 billion, reflecting growth of 14.7% to 19.5% over 2024 [14] - The strategic shift towards faster-burning therapeutic areas is expected to increase reimbursable costs as a percentage of revenue by 200 to 300 basis points over the remainder of the year [14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about accelerating revenue in the second half of the year due to improved funding, fewer cancellations, and rapid project start-ups [7][10] - The management acknowledged that while the funding environment has improved, there remains uncertainty regarding future cancellations and their impact on 2026 [29][30] Other Important Information - The company repurchased approximately 1.75 million shares for $518.5 million in Q2 2025, with $826.3 million remaining under the share repurchase authorization program [12][13] - The effective tax rate for 2025 is expected to be between 18.5% and 19% [14] Q&A Session Summary Question: What are the booking expectations for the second half? - Management expects bookings to increase, with a reasonable chance of getting the book-to-bill ratio back over 1.15, depending on cancellation rates [19] Question: Can you provide information on cancellations? - Cancellations were down across the entire portfolio, with rates lower than historical averages, contributing to better-than-expected bookings and performance [20] Question: How does the increase in pass-through costs impact revenue? - The increase in pass-through costs is expected to significantly influence revenue, with a large portion of the revenue increase attributed to accelerated reimbursable cost activity [24] Question: What is the outlook for funding and demand activity? - Management noted that while funding has improved, there is still uncertainty regarding potential future downturns in demand activity [30] Question: How did intra-quarter trends evolve in Q2? - The business environment remained strong throughout Q2, with low cancellation rates contributing to a stable demand environment [35] Question: What are the dynamics around bookings and competitive win rates? - The win rate was lower in Q2 due to the presence of large projects that were lost, but the overall number of decisions made increased significantly [48] Question: What is the expected hiring trend for the second half? - The company anticipates accelerated hiring in the second half, with a focus on maintaining mid to upper single-digit growth rates for the year [85]

Financial Performance - Revenue for Q2 2025 was $603.3 million, a 14.2% increase compared to $528.1 million in Q2 2024 [13, 21] - Year-to-date revenue reached $1,161.9 million, an 11.8% increase from $1,039.1 million in 2024 [13, 21] - EBITDA for Q2 2025 was $130.5 million, a 16.2% increase compared to $112.3 million in Q2 2024 [21] - Year-to-date EBITDA reached $249.1 million, a 9.3% increase from $227.9 million in 2024 [21] - Net income for Q2 2025 was $90.3 million, a 2.2% increase compared to $88.4 million in Q2 2024 [21] - Net income per diluted share for Q2 2025 was $3.10, a 12.7% increase compared to $2.75 in Q2 2024 [21] Business Trends - Net new business awards for Q2 2025 were $620.5 million, a 12.6% increase compared to $551.0 million in Q2 2024 [13] - Ending backlog was $2,873.6 million, a 1.8% decrease compared to $2,924.9 million in Q2 2024 [13] Cash Flow - Free cash flow for Q2 2025 was $142.4 million, compared to $103.5 million in Q2 2024 [39, 41] - Free cash flow conversion was 109.2% for Q2 2025, compared to 92.2% in Q2 2024 [39, 41] Guidance - Full year 2025 revenue guidance is $2,420.0 million - $2,520.0 million, representing a 14.7% - 19.5% growth rate [28, 43] - Full year 2025 EBITDA guidance is $515.0 million - $545.0 million, representing a 7.3% - 13.5% growth rate [28, 43]

Company Performance - Medpace reported quarterly earnings of $3.1 per share, exceeding the Zacks Consensus Estimate of $3 per share, and up from $2.75 per share a year ago, representing an earnings surprise of +3.33% [1] - The company posted revenues of $603.31 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 11.48%, compared to year-ago revenues of $528.1 million [2] - Over the last four quarters, Medpace has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance and Outlook - Medpace shares have declined approximately 6.1% since the beginning of the year, while the S&P 500 has gained 7.1% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at $2.95 for the coming quarter and $12.68 for the current fiscal year [4][7] - The estimate revisions trend for Medpace was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical Services industry, to which Medpace belongs, is currently in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - The performance of Medpace's stock may also be influenced by the overall industry outlook, as empirical research indicates a strong correlation between near-term stock movements and earnings estimate revisions [5][8]

Investor Contact: Lauren Morris 513.579.9911 x11994 l.morris@medpace.com Exhibit 99.1 FOR IMMEDIATE RELEASE Media Contact: Michael Maley 513.579.9911 x12831 m.maley@medpace.com Medpace Holdings, Inc. Reports Second Quarter 2025 Results CINCINNATI, OHIO, July 21, 2025-- Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Revenue for the three months ended June 30, 2025 increased 14.2% to $603.3 m ...

Core Viewpoint - The market anticipates Medpace (MEDP) will report a year-over-year increase in earnings driven by higher revenues in its upcoming earnings report for the quarter ended June 2025 [1][3]. Earnings Expectations - The consensus EPS estimate for Medpace is $3.00 per share, reflecting a year-over-year increase of +9.1% [3]. - Expected revenues for the quarter are $541.19 million, which is a 2.5% increase from the same quarter last year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 0.81%, indicating a reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Medpace is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.91%, suggesting a bearish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the likelihood of actual earnings deviating from consensus estimates, with positive readings being more reliable [9][10]. - Medpace currently holds a Zacks Rank of 3, which complicates the prediction of an earnings beat given the negative Earnings ESP [12]. Historical Performance - In the last reported quarter, Medpace exceeded the expected earnings of $3.06 per share by delivering $3.67, resulting in a surprise of +19.93% [13]. - The company has successfully beaten consensus EPS estimates in the last four quarters [14]. Conclusion - While Medpace does not appear to be a strong candidate for an earnings beat based on current estimates, investors should consider other factors before making investment decisions [17].

The latest trading session saw Medpace (MEDP) ending at $305.90, denoting a +2.54% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily gain of 0.55%. Elsewhere, the Dow saw an upswing of 0.25%, while the tech-heavy Nasdaq appreciated by 0.63%.Shares of the provider of outsourced clinical development services have depreciated by 4.91% over the course of the past month, underperforming the Medical sector's gain of 3.49% and the S&P 500's gain of 6.29%.The investm ...

Explore the exciting world of Medpace Holdings (MEDP 1.11%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!*Stock prices used were the prices of April 23, 2025. The video was published on May 27, 2025. ...

Core Insights - The article compares Concentra Group (CON) and Medpace (MEDP) to determine which stock offers better value for investors [1] - CON has a stronger Zacks Rank of 1 (Strong Buy) compared to MEDP's 3 (Hold), indicating a more favorable earnings outlook for CON [3][7] Valuation Metrics - CON has a forward P/E ratio of 15.59, significantly lower than MEDP's forward P/E of 26.38, suggesting CON is undervalued [5] - The PEG ratio for CON is 2.09, while MEDP's PEG ratio is higher at 3.58, indicating CON's expected earnings growth is more favorable relative to its valuation [5] - CON's P/B ratio stands at 9.44, compared to MEDP's 12.21, further supporting the notion that CON is a better value option [6] Value Grades - Based on various valuation metrics, CON holds a Value grade of B, while MEDP has a Value grade of C, reinforcing CON's position as the superior value stock [6]

Core Insights - The clinical trials market is projected to grow from US$ 58.39 billion in 2024 to US$ 99.25 billion by 2033, with a CAGR of 6.07% from 2025 to 2033, driven by various factors including healthcare demands and technological advancements [1][18]. Growth Drivers - The rising incidence of chronic illnesses is increasing the demand for effective treatment development, with significant global prevalence of diseases such as diabetes and cancer [3][4][5]. - The acceptance of decentralized clinical trials (DCTs) is enhancing patient participation and reducing logistical costs, making trials more efficient and patient-centered [6][7]. - The shift towards personalized medicine is expected to improve drug development success rates by utilizing pharmacogenetics, leading to increased investments in clinical trials by biopharmaceutical companies [8][9]. Market Dynamics - Phase III trials hold the largest market share due to their extensive patient involvement and higher costs, averaging over USD 19.0 million per trial [14]. - Oncology is the leading indication segment in the clinical trials market, attributed to the high prevalence of cancer and the number of ongoing trials [16]. - Interventional studies are projected to dominate the market, driven by the need for improved diagnostics and vaccines for viral diseases [17]. Challenges - Ethical and regulatory issues pose significant challenges for clinical trials, particularly those involving animal-based products, leading to increased costs and delays [10][11]. - Long trial durations and variability in individual responses complicate the clinical trial process, necessitating larger sample sizes and more complex methodologies [12][13].